65511-03-7

Basic information

• Product Name: (-)-2,3-dihydro-5,7-dihydroxy-2-methyl-4-quinolone
• Synonyms: (-)-2,3-dihydro-5,7-dihydroxy-2-methyl-4-quinolone
• CAS NO: 65511-03-7
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.19924
• EINECS: 265-802-7
• Mol File: 65511-03-7.mol

Chemical Properties

• Boiling Point: 448.2°Cat760mmHg
• Flash Point: 224.9°C
• Appearance: /
• Density: 1.326g/cm³
• Vapor Pressure: 1.2E-08mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: (-)-2,3-dihydro-5,7-dihydroxy-2-methyl-4-quinolone(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-2,3-dihydro-5,7-dihydroxy-2-methyl-4-quinolone(65511-03-7)
• EPA Substance Registry System: (-)-2,3-dihydro-5,7-dihydroxy-2-methyl-4-quinolone(65511-03-7)

Safety Data

• Hazardous Substances Data: 65511-03-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(-)-2,3-dihydro-5,7-dihydroxy-2-methyl-4-quinolone is used as a potential pharmaceutical compound for the development of new drugs. Its unique structure and biological activities make it a subject of interest for researchers in the pharmaceutical industry. It may be utilized in the treatment of various diseases and disorders, contributing to advancements in healthcare and medicine.

InChI:InChI=1/C10H11NO3/c1-5-2-8(13)10-7(11-5)3-6(12)4-9(10)14/h3-5,11-12,14H,2H2,1H3

Upstream product

• 107-93-7 (E)-but-2-enoic acid 
• 10272-07-8 3.5-dimethoxyaniline 
• 65510-83-0 3-(3,5-dimethoxyphenyl)aminobutyric acid ethyl ester 
• 1429484-69-4 3,5-dimethoxyaniline triflate 
• 1429484-70-7 methyl (S)-3-(3,5-dimethoxyphenylamino)butanoyl carbamate 
• 1429484-71-8 (S)-3-(3,5-dimethoxyphenylamino)butanoic acid 

Downstream Products

• 1429484-73-0 (2S)-1-formyl-5-hydroxy-2-methyl-4-oxo-3-(3-oxobutyl)-7-[(R)-5-phenyl-2-pentyloxy]-2,3-dihydroquinoline 
• 78513-72-1 (6S,6aR)-5,6,6a,7-tetrahydro-1-hydroxy-6-methyl-3-[(R)-5-phenyl-2-pentyloxy]benzo[c]quinoline-9(8H)-one 
• 1429484-74-1 (6S,6aR,10aR)-5,6,6a,7,10,10a-hexahydro-1-acetoxy-6-methyl-3-[(R)-5-phenyl-2-pentyloxy]benzo[c]quinoline-9(8H)-one 
• 77209-75-7 (6S,6aR,9R,10aR)-5,6,6a,7,8,9,10,10a-octahydro-1-acetoxy-9-hydroxy-6-methyl-3-[(R)-5-phenyl-2-pentyloxy]benzo[c]quinoline hydrochloride 
• 1429484-72-9 (S)-5-hydroxy-2-methyl-7-[(R)-5-phenyl-2-pentyloxy]-2,3-dihydroquinolin-4(1H)-one 
• 65511-11-7 d,l-5-hydroxy-2-methyl-7-(4-phenylbutyloxy)-4-oxo-1,2,3,4-tetrahydroquinoline 
• 65511-09-3 dl-5-hydroxy-2-methyl-7-(5-phenyl-2-pentyloxy)-4-oxo-1,2,3,4-tetrahydroquinoline 

Relevant articles and documents

Novel diphenylmethyl compounds having mycobacterium tuberculosis inhibitory activity

The invention relates to novel diphenylmethyl derivatives having mycobacterium tuberculosis inhibitory activity and a preparation method thereof and particularly relates novel diphenylmethyl derivatives having activity for inhibiting replicative and non-replicating mycobacterium tuberculosis and a preparation method thereof. In particular, the invention relates to compounds shown in the formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described in the specification. The invention also relates to the preparation method of the compounds and their pharmaceutical compositions and a use of the compounds in preparation of drugs for treating mycobacterium tuberculosis infection-caused diseases.

Derivatives of Natural Product Agrimophol as Disruptors of Intrabacterial pH Homeostasis in Mycobacterium tuberculosis

This article reports the rational medicinal chemistry of a natural product, agrimophol (1), as a new disruptor of intrabacterial pH (pHIB) homeostasis in Mycobacterium tuberculosis (Mtb). Through the systematic investigation of the structure-activity relationship of 1, scaffold-hopping of the diphenylmethane scaffold, pharmacophore displacement strategies, and studies of the structure-metabolism relationship, a new derivative 5a was achieved. Compound 5a showed 100-fold increased potency in the ability to reduce pHIB to pH 6.0 and similarly improved mycobactericidal activity compared with 1 against both Mycobacterium bovis-BCG and Mtb. Compound 5a possessed improved metabolic stability in human liver microsomes and hepatocytes, lower cytotoxicity, higher selectivity index, and similar pKa value to natural 1. This study introduces a novel scaffold to an old drug, resulting in improved mycobactericidal activity through decreasing pHIB, and may contribute to the critical search for new agents to overcome drug resistance and persistence in the treatment of tuberculosis.

Levonantradol: Asymmetric synthesis and structural analysis

The first asymmetric synthesis of a synthetic cannabinoid levonantradol was accomplished, and the 3-D solution structure of its core architecture was confirmed by NMR and computational methods. The Royal Society of Chemistry 2013.

1,9-Dihydroxyoctahydrobenzo[c]quinolines and 1-hydroxyhexahydrobenzo[c]quinoline-9(8H)-ones as antiemetic agents

1,9-Dihydroxyoctahydro[c]quinolines (I) and 1-hydroxyhexahydrobenzo[c]quinoline-9(8H)-ones (II), useful as antiemetic agents and derivatives thereof having the formulae STR1 wherein R is hydroxy or alkanoyloxy having from one to five carbon atoms; R1 is hydrogen, benzyl, benzoyl, alkanoyl having from one to five carbon atoms or --CO--(CH2)p --NR2 R3 wherein p is 0 or an integer from 1 to 4; each of R2 and R3 when taken individually is hydrogen or alkyl having from one to four carbon atoms; R2 and R3 when taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic ring (piperidino, pyrrolo, pyrrolidino, morpholino and N-alkylpiperazino having from one to four carbon atoms in the alkyl group); R4 is hydrogen, alkyl having from 1 to 6 carbon atoms and --(CH2)z --C6 H5 wherein z is an integer from 1 to 4; R5 is hydrogen, methyl or ethyl; R6 is hydrogen, --(CH2)y --carbalkoxy having from 1 to 4 carbon atoms in the alkoxy group wherein y is 0 or an integer from 1 to 4; carbobenzyloxy, formyl, alkanoyl having from two to five carbon atoms, alkyl having from one to six carbon atoms; --(CH2)x --C6 H5 wherein x is an integer from 1 to 4; and --CO(CH2)x-1 --C6 H5 ; Z is (a) alkylene having from one to nine carbon atoms; (b) --(alk1)m --X--(alk2)n -- wherein each of (alk1) and (alk2) is alkylene having from one to nine carbon atoms, with the proviso that the summation of carbon atoms in (alk1) plus (alk2) is not greater than 9; each of m and n is 0 or 1; X is O, S, SO or SO2 ; and W is hydrogen, methyl, STR2 wherein W1 is hydrogen, chloro or fluoro; pyridyl, piperidyl, cycloalkyl having from 3 to 7 carbon atoms, or monosubstituted cycloalkyl wherein the substituent is STR3 wherein W2 is hydrogen, chloro or fluoro; and pharmaceutically-acceptable acid addition salts of compounds of formulae I and II and the ketals of compounds of formula II wherein the ketal moiety has from two to four carbon atoms.